FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283726995> ?p ?o ?g. }

• W4283726995 endingPage "e004799" @default.
• W4283726995 startingPage "e004799" @default.
• W4283726995 abstract "Toll-like receptors (TLRs) are critical innate immune sensors that elicit antitumor immune responses in cancer immunotherapy. Although a few TLR agonists have been approved for the treatment of patients with early-stage superficial cancers, their therapeutic efficacy is limited in patient with advanced invasive cancers. Here, we identified the therapeutic role of a TLR2/3 agonist, L-pampo (LP), which promotes antitumor immunity and enhances the immune checkpoint blockade.We generated LP by combining a TLR2 agonist, Pam3CSK4, with a TLR3 agonist, Poly (I:C). Immune responses to stimulation with various TLR agonists were compared. Tumor-bearing mice were intratumorally treated with LP, and their tumor sizes were measured. The antitumor effects of LP treatment were determined using flow cytometry, multiplexed imaging, and NanoString nCounter immune profiling. The immunotherapeutic potential of LP in combination with α-programmed cell death protein-1 (PD-1) or α-cytotoxic T-lymphocytes-associated protein 4 (CTLA-4) was evaluated in syngeneic MC38 colon cancer and B16F10 melanoma.The LP treatment induced a potent activation of T helper 1 (Th1) and 2 (Th2)-mediated immunity, tumor cell apoptosis, and immunogenic tumor cell death. Intratumoral LP treatment effectively inhibited tumor progression by activating tumor-specific T cell immunity. LP-induced immune responses were mediated by CD8+ T cells and interferon-γ, but not by CD4+ T cells and CD25+ T cells. LP simultaneously activated TLR2 and TLR3 signaling, thereby extensively changing the immune-related gene signatures within the tumor microenvironment (TME). Moreover, intratumoral LP treatment led to systemic abscopal antitumor effects in non-injected distant tumors. Notably, LP treatment combined with ɑPD-1 and ɑCTLA-4 further enhanced the efficacy of monotherapy, resulting in complete tumor regression and prolonged overall survival. Furthermore, LP-based combination immunotherapy elicited durable antitumor immunity with tumor-specific immune memory in colon cancer and melanoma.Our study demonstrated that intratumoral LP treatment improves the innate and adaptive antitumor immunity within the TME and enhances the efficacy of αPD-1 and αCTLA-4 immune checkpoint blockade." @default.
• W4283726995 created "2022-07-01" @default.
• W4283726995 creator A5008078153 @default.
• W4283726995 creator A5018933458 @default.
• W4283726995 creator A5036899937 @default.
• W4283726995 creator A5047099233 @default.
• W4283726995 creator A5058106720 @default.
• W4283726995 creator A5062010857 @default.
• W4283726995 creator A5066759908 @default.
• W4283726995 creator A5071440493 @default.
• W4283726995 creator A5078343284 @default.
• W4283726995 creator A5079170119 @default.
• W4283726995 creator A5083719649 @default.
• W4283726995 creator A5090333957 @default.
• W4283726995 date "2022-06-01" @default.
• W4283726995 modified "2023-09-30" @default.
• W4283726995 title "Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade" @default.
• W4283726995 cites W1934712179 @default.
• W4283726995 cites W2033023829 @default.
• W4283726995 cites W2063155121 @default.
• W4283726995 cites W2114013079 @default.
• W4283726995 cites W2143772132 @default.
• W4283726995 cites W2145216692 @default.
• W4283726995 cites W2509733466 @default.
• W4283726995 cites W2587048937 @default.
• W4283726995 cites W2618210811 @default.
• W4283726995 cites W2791483720 @default.
• W4283726995 cites W2800750353 @default.
• W4283726995 cites W2809991672 @default.
• W4283726995 cites W2834234275 @default.
• W4283726995 cites W2884394230 @default.
• W4283726995 cites W2888828176 @default.
• W4283726995 cites W2896033748 @default.
• W4283726995 cites W2900611152 @default.
• W4283726995 cites W2902185751 @default.
• W4283726995 cites W2904883738 @default.
• W4283726995 cites W2919995737 @default.
• W4283726995 cites W2921693673 @default.
• W4283726995 cites W2947646427 @default.
• W4283726995 cites W2963305393 @default.
• W4283726995 cites W2973192833 @default.
• W4283726995 cites W2995764816 @default.
• W4283726995 cites W3003147104 @default.
• W4283726995 cites W3009837239 @default.
• W4283726995 cites W3012283572 @default.
• W4283726995 cites W3015860015 @default.
• W4283726995 cites W3027564689 @default.
• W4283726995 cites W3033852017 @default.
• W4283726995 cites W3034777343 @default.
• W4283726995 cites W3045065939 @default.
• W4283726995 cites W3049075450 @default.
• W4283726995 cites W3091083933 @default.
• W4283726995 cites W3091442760 @default.
• W4283726995 cites W3093295415 @default.
• W4283726995 cites W3095848686 @default.
• W4283726995 cites W3103927660 @default.
• W4283726995 cites W3165868809 @default.
• W4283726995 cites W3168539558 @default.
• W4283726995 cites W3174298209 @default.
• W4283726995 cites W3178981994 @default.
• W4283726995 cites W3186709864 @default.
• W4283726995 cites W3187814006 @default.
• W4283726995 cites W3188379617 @default.
• W4283726995 cites W3200593920 @default.
• W4283726995 cites W3207771810 @default.
• W4283726995 cites W4200154868 @default.
• W4283726995 cites W4205315499 @default.
• W4283726995 doi "https://doi.org/10.1136/jitc-2022-004799" @default.
• W4283726995 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35764365" @default.
• W4283726995 hasPublicationYear "2022" @default.
• W4283726995 type Work @default.
• W4283726995 citedByCount "8" @default.
• W4283726995 countsByYear W42837269952022 @default.
• W4283726995 countsByYear W42837269952023 @default.
• W4283726995 crossrefType "journal-article" @default.
• W4283726995 hasAuthorship W4283726995A5008078153 @default.
• W4283726995 hasAuthorship W4283726995A5018933458 @default.
• W4283726995 hasAuthorship W4283726995A5036899937 @default.
• W4283726995 hasAuthorship W4283726995A5047099233 @default.
• W4283726995 hasAuthorship W4283726995A5058106720 @default.
• W4283726995 hasAuthorship W4283726995A5062010857 @default.
• W4283726995 hasAuthorship W4283726995A5066759908 @default.
• W4283726995 hasAuthorship W4283726995A5071440493 @default.
• W4283726995 hasAuthorship W4283726995A5078343284 @default.
• W4283726995 hasAuthorship W4283726995A5079170119 @default.
• W4283726995 hasAuthorship W4283726995A5083719649 @default.
• W4283726995 hasAuthorship W4283726995A5090333957 @default.
• W4283726995 hasBestOaLocation W42837269951 @default.
• W4283726995 hasConcept C136449434 @default.
• W4283726995 hasConcept C154317977 @default.
• W4283726995 hasConcept C167672396 @default.
• W4283726995 hasConcept C202751555 @default.
• W4283726995 hasConcept C203014093 @default.
• W4283726995 hasConcept C2776090121 @default.
• W4283726995 hasConcept C2776107976 @default.
• W4283726995 hasConcept C2776709828 @default.
• W4283726995 hasConcept C2777701055 @default.
• W4283726995 hasConcept C2778420691 @default.

• next